01/24/2017
Bio-Rad Launches Amplichek STI, the Third in a Series of Quality Controls for the Molecular Diagnostics Testing Market
11/21/2016
Bio-Rad Laboratories, Inc. today announced CE IVD marking for its BioPlex 2200 Syphilis Total & RPR assay, a novel universal testing method to aid in the diagnosis of syphilis infection.
10/24/2016
Bio-Rad Laboratories, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market.
08/02/2016
Bio-Rad Launches Amplichek I Quality Control, the Second in a Series of Controls for the Molecular Diagnostics Testing Market
06/06/2016
Bio-Rad Announces the Release of Liquichek™ Maternal Serum II Control. The Multi-Constituent Control Offers Increased Efficiency and Confidence in Test Results.
02/25/2016
Researchers can use the QX200 system for highly-accurate detection and quantification of nucleic acids, aiding clinical decision-making in the treatment of diseases ranging from cancer to transplant rejection and viral infection.
09/28/2015
Bio-Rad announced the launch of human recombinant protein antigens, which expand the company’s critical raw material offering.
08/25/2015
Bio-Rad Laboratories announced the launch of Bio-Rad Mission: Control™, the first objective risk management software to help laboratories identify the best QC rules and the right QC frequency to develop a customized quality control plan to deliver reliable test results.
06/15/2015
Bio-Rad Laboratories will complete a business systems update on July 6. Impacts to business operations will be minimal, but North American customers should note that Bio-Rad will not ship products from July 1–July 5; shipping will resume on July 6. New customer account numbers and other changes to customer-facing data formats will also be implemented on this date.
11/20/2014
Bio-Rad Laboratories' Geenius HIV-1/HIV-2 Supplemental Assay can differentiate circulating antibodies to Human Immunodeficiency Virus Types 1 and 2 in whole blood, serum and plasma. Earlier this month, the company announced that it received Premarket Application Approval from the U.S. Food and Drug Administration for the assay.